AZ Hematology Hub

Featured Moments highlights of international experts' sessions captured in short videos.

 

 

Precision Approach for CLL Management

CLL Management in Clinic

Dr. Ruba Taha, Qatar

CLL Risk Stratification

Dr. Kostas Stamatopoulos, Greece

Optimizing CLL Management

Dr. Salem Alshemmari, Kuwait

Translating Data into Practice

Dr. Ayman Ibrahim, Saudi Arabia

Panel Discussion

Dr. Feras Al Fraih, KSA

CLL Management 2023 - Year in Review

(26th February 2023)

Review on Time to Progression Regimen in CLL Management

Dr. George Follows, UK

The CLL Management in Clinic

Dr. Hani Osman, UAE

Translating Data Into Practice

Dr. Ihab El-Hemaidi, KSA

Review on Fixed Duration Regimen in CLL Management

Dr. Mahmoud Marashi, UAE

Panel Discussion

Dr. Feras Al Fraih, KSA

Applying guideline updates and real-world experience in CLL

CLL Case Presentation

Dr. Khalil Al Farsi, Oman

2nd GCC Haematology Forum- CLL Case Discussion Focus on Safety Profile of BTKi

Dr. Ruba Taha, Qatar

Expert Guidance for the Treatment of CLL

Dr. Susan M. O'Brien, US

Panel Discussion

Dr. Ayman Al Hejazi, KSA

EHA & ASCO updates in B-Cell malignancies

Panel Discussion

Dr. Ahmad Absi, KSA

Latest Updates in Management of CLL

Dr. Davide Rossi, Switzerland

CLL Management in Clinic

Dr. Faraz Khan, UAE

Translating Data Into Practise

Dr. Ramesh Pandita, Kuwait

Lates Updates in Management of Non-Hodgkin Lymphoma

Dr. Alfadel AL Shaibani, KSA

Precision approach for CLL treatment (26th June 2022)

Impact of Comorbidities and AEs on the Treatment Choice for CLL Patients

Dr. Ahmad Alhuraiji, Kuwait

CLL Management in Clinic

Dr. Aamer Aleem, KSA

How to Choose BTK Inhibitors for CLL Patients?

Dr. Krish Patel, US

Translating Data Into Practice

Dr. Shabeeha Rana, UAE

Panel Discussion

Dr. Amal Al-Beihany, KSA

High-risk CLL in the era of Novel Agents

Definition and Management of High-Risk CLL Patients

Dr. Ayman Al Hejazi, KSA

Continues Therapy Versus Time Limited Therapy in High-Risk CLL Patients

Dr. Wojciech Jurczak , Poland

Translating Data Into Practice

Dr. Iman Alhazmi, KSA

CLL Management in Clinic

Dr. Amar Lal, UAE

Panel Discussion

Dr. Arif Alam, UAE

Updates in Management of MCL

Translating Data Into Practice

Dr. Ghazi Alotaibi, KSA

Acalabrutinib and Other Novel Therapies in Mantle Cell Lymphoma

Dr. Michael Wang, US

MCL Management in Clinic

Dr. Salem Alshemmari, Kuwait

Management of Treatment Naïve Mantle Cell Lymphoma

Dr. Mustaqeem Siddiqui, UAE

Panel Discussion

Dr. Abdulaziz Hamadah, Kuwait

Adverse Events burden and management in 
CLL treatments (27th March 2022)

Optimizing the Usage of BTK Inhibitors in CLL

Dr. Cyrus Khan, US

CLL Management Inside the Clinic

Dr. Hassan Aljasem, KSA

Translating Data Into Practice

Dr. Husni Al Hateeti, UAE

Burden of Comorbidities & Adverse Events in CLL

Dr. Musa Al Zahrani, KSA

Panel Discussion

Dr. Amar Lal, UAE

BTKi review in management of CLL

Translating Data Into Clinical Practice

Dr. Abdulkareem Algarni, KSA

Critical Evaluation of BTKis in CLL

Dr. George Follows, UK

CLL Management Inside the Clinic

Dr. Hani Yousif Osman , UAE

Evolvement of CLL Management

Dr. Mahmoud Marashi, UAE

Panel Discussion

Dr. Ahmad Absi, KSA